CETP inhibitors and cardiovascular disease: Time to think again

F1000Research

Volumn 3, Issue , 2014, Pages

  Miller, Norman E ^a  

^a MAGDALEN COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALLELE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; COHORT ANALYSIS; GENE TRANSFER; GENETIC ASSOCIATION; HEART INFARCTION; HUMAN; IN VIVO STUDY; MACROPHAGE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PROSPECTIVE STUDY; RABBIT; RISK FACTOR;

EID: 84914810740     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.4396.1     Document Type: Article

References (55)

1. Fielding CJ Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36(2):211-28. 7751809
2. Fielding CJ Havel RJ: Cholesteryl ester transfer protein: friend or foe? J Clin Invest. 1996;97(12):2687-8. 8675675 10.1172/JCI118719 507357
3. Hennessy LK Kunitake ST Kane JP: Apolipoprotein A-I-containing lipoproteins, with or without apolipoprotein A-II, as progenitors of pre-beta high density lipoprotein particles. Biochemistry. 1993;32(22):5759-65. 8504094 10.1021/bi00073a006
4. Marotti KR Castle CK Boyle TP: Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 1993;364(6432):73-5. 8316302 10.1038/364073a0
5. Okamoto H Yonemori F Wakitani K: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406(6792):203-7. 10910363 10.1038/35018119
6. Sugano O Makino N Sawada S: Effect of antisense oligonucleotides against cholesteryl transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273(9):5033-6. 9478952 10.1074/jbc.273.9.5033
7. Ritterhaus CW Miller DP Thomas LJ: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20(9):2106-12. 10978256 10.1161/01.ATV.20.9.2106
8. Hayek T Masucci-Magoulas L Jiang X: Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995;96(4):2071-4. 7560101 10.1172/JCI118255 185846
9. Föger B Chase M Amar MJ: Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem. 1999;274(52):36912-20. 10601244 10.1074/jbc.274.52.36912
10. Curb JD Abbott RD Rodriguez BL: A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004;45(5):948-53. 14967821 10.1194/jlr.M300520-JLR200
11. Thompson A Di Angelantonio E Sarwar N: Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777-88. 18560005 10.1001/jama.299.23.2777
12. Li YY Wu XY Xu J: Apo A5 -1131T/C, FgB -455G/A, -148C/T, and CETP TaqIB gene polymorphisms and coronary artery disease in the Chinese population: a meta-analysis of 15,055 subjects. Mol Biol Rep. 2013;40(2):1997-2014. 23129316 10.1007/s11033-012-2257-9
13. Dullaart RP Sluiter WJ: Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics. 2008;9(6):747-63. 18518852 10.2217/14622416.9.6.747
14. Barter PJ Caulfield M Eriksson M: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-22. 17984165 10.1056/NEJMoa0706628
15. Schwartz GG Olsson AG Abt M: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-99. 23126252 10.1056/NEJMoa1206797
16. Boekholdt SM Kuivenhoven JA Wareham NJ: Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the Prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk population study. Circulation. 2004;110(11):1418-23. 15337694 10.1161/01.CIR.0000141730.65972.95
17. Ritsch A Auer B Foger B: Polyclonal antibody-based immunoradiometric assay for quantification of cholesteryl ester transfer protein. J Lipid Res. 1993;34(4):673-79. 8496672
18. Marschang P Sandhofer A Ritsch A: Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med. 2006;260(2):151-9. 16882279 10.1111/j.1365-2796.2006.01674.x
19. Vasan RS Pencina MJ Robins SJ: Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation. 2009;120(24):2414-20. 19948972 10.1161/CIRCULATIONAHA.109.872705 2818786
20. Khera AV Wolfe ML Cannon CP: On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol. 2010;106(4):451-6. 20691300 10.1016/j.amjcard.2010.03.057
21. Duwensee K Breitling LP Tancevski I: Cholesteryl ester transfer protein in patients with coronary heart disease. Eur J Clin Invest. 2010;40(7):616-22. 20497463 10.1111/j.1365-2362.2010.02313.x
22. Ritsch A Scharnagl H Eller P: Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2010;121(3):366-74. 20065167 10.1161/CIRCULATIONAHA.109.875013 2964596
23. Robins SJ Lyass A Brocia RW: Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis. 2013;228(1):230-6. 23477743 10.1016/j.atherosclerosis.2013.01.046 3692011
24. Ridker PM Paré G Parker AN: Polymorphism of the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2(1):26-33. 20031564 10.1161/CIRCGENETICS.108.817304 2729193
25. Voight BF Peloso GM Ortho-Melander M: Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-80. 22607825 10.1016/S0140-6736(12)60312-2 3419820
26. Smith GD Ebrahim S: Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30-42. 15075143 10.1093/ije/dyh132
27. Sleiman PM Grant SF: Mendelian randomization in the era of genomewide association studies. Clin Chem. 2010;56(5):5723-8. 20224045 10.1373/clinchem.2009.141564
28. Barsh GS Copenhaver GP Gibson G: Guidelines for genome-wide association studies. PLoS Genet. 2012;8(7):e1002812. 22792080 10.1371/journal.pgen.1002812 3390399
29. Sandhofer A Tatarczyk T Laimer M: The Taq1B-variant in the cholesteryl ester-transfer protein gene and the risk of metabolic syndrome. Obesity (Silver Spring). 2008;16(4):919-22. 18239576 10.1038/oby.2007.130
30. Leusink M Onland-Moret NC Asselbergs FW: Cholesteryl ester transfer protein polymorphisms, statin use and their impact on cholesterol levels and cardiovascular events. Clin Pharmacol Ther. 2014;95(3):314-20. 24080640 10.1038/clpt.2013.194
31. Papp AC Pinsonneault JK Wang W: Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One. 2012;7(3):e31930. 22403620 10.1371/journal.pone.0031930 3293889
32. Tanigawa H Billheimer JT Tohyama J: Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation. 2007;116(11):1267-73. 17709636 10.1161/CIRCULATIONAHA.107.704254
33. Tchoua U D'Souza W Mukhamedova N: The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res. 2008;77(4):732-9. 18056760 10.1093/cvr/cvm087
34. Villard EF El Khoury P Duchene E: Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women. Arterioscler Thromb Vasc Biol. 2013;32(10):2341-9. 22904275 10.1161/ATVBAHA.112.252841
35. Borggreve SE de Vries R Dallinga-Thie GM: The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C-->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin: cholesterol acyltransferase activity. Biochim Biophys Acta. 2008;1781(1-2):10-5. 18178167 10.1016/j.bbalip.2007.10.010
36. Scharnag lH Heuschneider C Sailer S: Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels. Eur J Clin Invest. 2014;44(4):395-401. 24467215 10.1111/eci.12248
37. Yamashita S Ishigami M Arai T: Very high density lipoproteins induced by plasma cholesteryl ester transfer protein (CETP) have a potent antiatherogenic function. Ann N Y Acad Sci. 1995;748:606-8. 7695214 10.1111/j.1749-6632.1994.tb17372.x
38. Shimoji E Zhang B Fan P: Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits. Atherosclerosis. 2004;172(2):247-57. 15019534 10.1016/j.atherosclerosis.2003.09.029
39. Duverger N Kruth H Emmanuel F: Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 1996;15(4):94:713-7. 8772693 10.1161/01.CIR.94.4.713
40. Brousseau ME Diffenderfer MR Millar JS: Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25(5):1057-64. 15761191 10.1161/01.ATV.0000161928.16334.dd 3229922
41. Oshima R Ikeda T Watanabe K: Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis. 1998;137(1):13-22. 9568732 10.1016/S0021-9150(97)00243-8
42. Ying H Saku K Harada R: Putative mechanisms of action of probucol on high-density lipoprotein apolipoprotein A-I and its isoproteins kinetics in rabbits. Biochim Biophys Acta. 1990;1047(3):247-54. 2123720 10.1016/0005-2760(90)90523-Z
43. Barter PJ Rye KA Beltangady MC: Relationship between atorvastatin dose and the harm caused by torcetrapib. J Lipid Res. 2012;53(11):2436-42. 22941786 10.1194/jlr.P026328 3466012
44. Barter PJ Rye KA: Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res. 2012;53(9):1755-66. 22550134 10.1194/jlr.R024075 3413218
45. Durrington PN: Cholesteryl ester transfer protein (CETP) inhibitors. Br J Cardiol. 2012;19:126-33. 10.5837/bjc.2012.024
46. Hewing B Fisher EA: Rationale for cholesteryl ester transfer protein inhibitors. Curr Opin Lipidol. 2012;23(4):372-6. 22517614 10.1097/MOL.0b013e328353ef1d 3924318
47. Shinkai H: Cholesteryl ester transfer protein inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag. 2012;8:323-31. 22661899 10.2147/VHRM.S25238 3363149
48. Miyares MA Davis K: Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dydlipidaemia: focus on anacetrapib. Vasc Health Risk Manag. 2012;8:483-93. 22977305 10.2147/VHRM.S29010 3430392
49. deGoma EM Rader DJ: High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein? J Am Coll Cardiol. 2012;60(8):517-20. 22796252 10.1016/j.jacc.2012.03.058
50. Kingwell BA Chapman MJ Kontush A: HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov. 2014;13(6):445-64. 24854407 10.1038/nrd4279
51. A study of evacetrapib in high risk vascular disease. Reference Source
52. Nicholls SJ Brewer HB Kastelein JJ: Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306(19):2099-109. 22089718 10.1001/jama.2011.1649
53. Randomized evaluation of the effects of anacetrapib through lipid-modification. Reference Source
54. Cannon CP Shah S Dansky HM: Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406-15. 21082868 10.1056/NEJMoa1009744
55. Karlberg JPE Speers MA: Reviewing clinical trials: A guide for ethics committees.2010. Reference Source